Chongqing Genrix Bio Pharmaceutical Co., Ltd, a Chinese biopharmaceutical company, has received marketing approval from China’s National Medical Products Administration (NMPA) for its self-developed Category 1 biologic product, xeligekimab. This marks the first domestically developed anti-IL-17 antibody in China approved for the treatment of moderate-to-severe plaque psoriasis.
The introduction of xeligekimab to the market is significant as it joins other similar products with the same indication, such as Novartis’s Cosentyx (secukinumab) and Eli Lilly’s Taltz (ixekizumab). The approval is supported by robust clinical trial results from a Phase III study, which was a randomized, double-blinded, placebo-controlled, multi-center trial. The study demonstrated xeligekimab’s excellent efficacy and good safety and tolerability profile.- Flcube.com
